INTRODUCTION
good prognostic value for prognosis of patients with chronic hepatitis C (CHC). 12 However, only a few studies in literature have evaluated prognostic value of NIFS for the long-term survival of PBC population.
The present study was performed to explore prognostic value of several widely used NIFS for the mortality due to liver-related events in Chinese PBC population.
METHODOLOGY
It was observational study where all patients diagnosed with PBC and treated at the Second Hospital of Shandong University were recruited between August 2008 and July 2018. The diagnosis of PBC should fulfill at least two of the following criteria: 1 (1) presence of anti-mitochondrial antibodies (AMA), or other PBC-specific autoantibodies, including anti-sp100 or anti-glycoprotein 210 (anti-gp210); (2) biochemical evidence of cholestasis (elevated ALP levels); and (3) histological evidence of liver biopsy, such as non-suppurative destructive cholangitis and destruction of interlobular bile ducts. Patients were excluded if they were: just started UDCA administration within last year, followed up for less than one year, diagnosed as overlap syndrome, suffered from other coexisting hepatic diseases including chronic hepatitis B (CHB) and CHC infection, alcoholic liver disease, steatohepatitis, and hereditary metabolic liver disease.
Patients' age, gender, platelet count, liver biochemistry, creatinine, and international normalised ratio (INR) were recorded. Scores of 11 NIFS deriving from blood tests for pre-treatment assessment of liver fibrosis were calculated, including fibrosis-4 index, Lok score, Fibroalpha, GUCI score, AST-ALT ratio (AAR), Fibrosis index, Fibro-Q score, Doha score, Age platelet count index, King's score and AST-platelet count ratio index (APRI) ( Table I) . 12, 13 The endpoint event was set as death due to liver-related events, such as hepatocellular carcinoma (HCC), hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome and gastrointestinal bleeding.
The protocol of the current study followed guidelines of the Helsinki Declaration and has been approved by the Ethical Committee of the Second Hospital of Shandong University.
All data were analysed using IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, USA). Kolmogorov-Smirnov test was performed to calculate the normality of continuous variables. Data were expressed by using mean ± standard deviation (SD) or median [interquartile range (IQR)] for continuous variables. Student t-test or Mann-Whitney test were selected for the comparisons of continuous statistics. Cox proportional hazards model was performed to explore independent predictors of liver-related mortality. Covariates brought into multivariable analysis included: age at diagnosis of PBC, gender, alanine aminotransferase (ALT), aspartate aminotransferas (AST), GGT, TB, albumin, platelet count, INR, creatinine, and a specific NIFS. If some covariates were included in the given NIFS, they were removed from the multivariable analysis. A p-value less than 0.05 was considered as statistically significant. 12, 20 NIFS Calculations Age was expressed as years; ALT and AST were expressed as U/L; PLT was expressed as 10 9 /L; AFP was expressed as IU/ml; albumin was expressed as g/dl. Figure I) . Non-survival patients were characterised with lower platelet count (p=0.049) and lower level of albumin (p=0.018, Table II ).
The predictive value of 11 generally accepted NIFS were evaluated (Table I) . Fibrosis index (p<0.001) and Doha score (p=0.006) were significantly higher in non-survival PBC patients (Table II ). Univariate analysis revealed that higher Fibrosis-4 index (p=0.009), GUCI score (p=0.015), Fibrosis index (p=0.008), Doha score (p=0.010), Age platelet count index (p=0.026), King's score (p=0.008) and APRI (p=0.015) may be related to worse clinical prognosis (death because of liver-related events). However, in multivariate Cox regression analysis, only Fibrosis index (HR 17.449, 95% CI 1.410-215.989, p=0.026) and Doha score (HR 1.782, 95% CI 1.146-2.771, p=0.010) were identified as independent predictors for liver-related mortality of PBC population (Table III ) .
DISCUSSION
Although several models including baseline characteristics and biochemical response to UDCA have been approved to predict long-term outcomes of PBC, the prognostic value of parameters prior to initiating therapy is still unknown. Cirrhosis has been identified as an independent predictor for transplant-free survival in Chinese PBC patients; 3, 14 however, the diagnosis of cirrhosis made by imaging features or findings of portal hypertension (including ascites, splenomegaly and varices) may be delayed and have low sensitivity. NIFS are routinely available in clinical practice and have been widely used for the evaluation of liver fibrosis and cirrhosis. 12, 13 Therefore, the evaluation of NIFS prior to UDCA therapy for long-term survival of PBC patients is promising and should be of great clinical significance.
The current study attempts to explore the prognostic value of several widely used NIFS for the mortality due to liver-related events in Chinese PBC population. arriving from liver function tests and other routine blood tests to identify Fibrosis index and Doha score as valuable prognostic factors.
Parameters contained in both Fibrosis index and Doha score included serum albumin and platelet count. Albumin could reflect the synthetic ability of hepatocytes. Lower levels of albumin at the time of diagnosis have been proven to identify PBC patients with a worse prognosis. 4, 10, 11, 15 A 10-year observational UDCAtreated PBC cohort also revealed that the long-term survival of PBC population with normal levels of bilirubin and albumin could be comparable to that of general population. 16 The above findings emphasised the prognostic value of albumin. Platelet counts could reflect the level of portal hypertension and has been considered as a serum marker of liver fibrosis and cirrhosis. Previous studies also revealed the prognostic value of platelet count for adverse events. 2, 10, 11 The baseline levels of albumin and platelet count were also evaluated in two recently developed scoring systems for outcomes of PBC (the GLOBE, 10 and UK-PBC systems), 11 revealing the validated prognostic value of the two parameters.
Trivedi et al. concluded that higher APRI is associated with risk of liver transplant (LT) or death. 2 In this study, the prognostic value of APRI was also significant in univariate analysis (p=0.015); however, in multivariate Cox regression analysis, ARPI was not related to the mortality due to liver-related events. The difference might be because of the interaction of different parameters (e.g. AST, bilirubin, albumin and platelet count). Discrepancy of PBC patients between Western and Asian countries should also be considered. Further validation with larger cohort is needed in the future.
Yang et al. reported that anti-gp210 could serve as a predictive indicator for the prognosis of Chinese PBC population and should be an important supplement to the GLOBE score and UK-PBC score. 15 As positive anti-gp210 in PBC patients is correlated with more severe cholestatic manifestations and higher risk of liver failure, 15, 17 the combined prognostic value of anti-gp210 and Fibrosis index or Doha score should be investigated. However, only a small proportion of included PBC patients in our cohort were examined with anti-gp210 and this parameter was not brought into the current statistical analysis.
In the present cohort, 5 patients died because of liverrelated events during a median of 35-month follow-up. The 5-year cumulative survival rate was 88.4%, which was consistent with previous studies performed in Asian populations. 14, 18 The incidences of HCC were as low as 0.76%-5.9% in PBC patients, 19 and were mainly found in patients with advanced stage of the disease. 17 In the current study, HCC occurred in 2 patients (3.1%) after 12 and 48 months' follow-up, respectively, which was also similar to previous studies. 14, 18, 19 Both of HCC patients were diagnosed in cirrhotic status before the start of UDCA. The present study did not explore the risk factors for HCC because of the limited number of carcinoma patients.
There are several limitations of the present study. First, the sample size was relatively small. However, the results were valid, which were consistent with the performance of various prognostic models. Second, the relatively short follow-up time (range 12 to 108 months) may restrict some prognostic models in predicting clinical outcomes after long-term follow-up, which may omit some valuable NIFS.
CONCLUSION
Two valuable NIFS (Fibrosis index and Doha score) arriving from routine pretreatment laboratory parameters were identified for the evaluation of liver-related mortality in Chinese PBC population. These predictive NIFS can be applied easily before treatment of PBC and may be helpful in the evaluation of long-term prognosis.
